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ABSTRACT 
Objective: This study was aimed to design and characterize Paclitaxel-loaded Solid Lipid Nanoparticles (SLNs) to achieve site specificity,reduce 
toxicity and sustained release pattern.  
Methods: Paclitaxel-loaded solid lipid nanoparticles were fabricated by microemulsion followed by probe sonication technique using stearic acid as lipid and 
stabilized of the mixture of surfactants. In this study, 32
Results: The results showed that the paclitaxel-loaded solid lipid nanoparticles prepared with the concentration of 33.31 % stearic acid and 500 mg 
of soya lecithin were optimum characteristic than other formulations. They showed the average particles size 149±4.10 nm and PDI 250±2.04. The 
zeta potential, % EE and % drug loading capacity was found to be respectively-29.7, 93.38±1.90 and 0.81±0.01. The optimized batch of Paclitaxel 
SLNs exhibited spherical shape with smooth surface analyzed by Transmission Electron Microscopy. In vitro study showed sustained release profile 
and was found to follow Higuchi Kinetics Equation.  
 full factorial design was employed for optimizing the concentration of lipid as stearic acid and 
surfactant (soya lecithin) for the nanoparticles. The optimization was done by studying the dependent variable of particle size and % entrapment efficiency.  
Conclusion: The SLNs of paclitaxel m et al. l the requirements of a colloidal drug delivery system. They had a particle size in nanosize; their size 
distribution was narrow and all the particles were in a spherical shape.  
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Paclitaxel is a diterpenoid pseudo alkaloid isolated from the Pacific 
Yew tree (Taxus brevifolia, Family Taxaceae) [1-5]. Paclitaxel has 
antineoplastic activity, being used against a wide spectrum of cancers. 
Paclitaxel is prescribed to treat most aggressive forms of ovarian, lung, 
head, neck, breast carcinoma and acute leukemia [6]. It is a taxane 
which interferes with microtubule depolymerization in tumor cells 
resulting in an arrest of the cell cycle in mitosis followed by induction 
of apoptosis [7]. However, the success of its clinical application is 
limited by its low therapeutic index and low water solubility due to its 
extreme hydrophobic character. The available marketed dosage forms 
of paclitaxel are Taxol® and Abraxane®. Taxol® is an intravenous 
infusion, which composed of 50:50 (v/v) cremophor EL 
(polyethoxylated castor oil) and dehydrated alcohol. Taxol shows 
serious side effects such as hypersensitivity, nephrotoxicity, 
neurotoxicity and cardiotoxicity attributable to paclitaxel or 
cremophor EL or both [8, 9]. It is also cumbersome for the patients and 
limits the use of frequent dosing schedule for prolonged systemic 
exposure to the drug. To eliminate cremophor EL from paclitaxel 
formulation, many alternative cremophor EL free formulations have 
been investigated. Abraxane® is a cremophor EL free paclitaxel 
formulation and was registered with FDA in 2005. Its clinical profile 
was improved but generally, Abraxane® is not replacing Taxol®in 
cancer chemotherapy mostly due to its higher cost. Therefore to avoid 
the side effects and higher cost of the above formulations, there is a 
need to develop alternative nanocarriers system for paclitaxel [10]. 
Nanoparticles offer an alternative delivery system for cancer 
therapy that has the potential to control the release rate of drug, 
improve the drug pharmacokinetics and biodistribution, and reduce 
drug toxicity. Due to their small size, nanoparticles with entrapped 
drugs may penetrate tumors due to the discontinuous and leaky 
nature of the microvasculature of tumors [11, 12]. 
Lipid-based particulate delivery systems, like liposomes, micelles, 
nanocapsules, and solid lipid nanoparticles have been developed 
especially to solubilize poorly water-soluble and lipophillic drugs. 
These lipid-based systems have the advantage that comprises bio-
derived and/or biocompatible lipids that often result in lower toxicity. 
An experimental design is a statistical technique used to simultaneously 
analyze the influence of multiple factors on the properties of the system 
being studied. The purpose of experimental design is to plan and conduct 
experiments in order to extract the maximum amount of information 
from the collected data in the smallest number of experimental runs. 
Factorial design based on response surface method has been applied to 
design formulations [13, 14]. 
In the present study we investigated the possibility and potential of 
incorporating paclitaxel in SLNs made up of bio-acceptable and 
biodegradable lipid; stearic acid, using a microemulsion method and 
stabilized by a mixture of surfactants; soya lecitihin and poloxamer 
P-407 to produce stable and smaller sized nanoparticles with an aim 
to evaluate them as carrier for parenteral administration of 
paclitaxel. The effect of various concentrations of stearic acid and 
soya lecithin was analyzed for its influence on particle properties 
such as SLNs particle size, particle shape, zeta potential, entrapment 
efficiency, drug loading capacity and drug release profile.  
MATERIALS AND METHODS 
Material 
Paclitaxel (Khandelwal Laboratories Pvt. Ltd. Thane), stearic acid, 
poloxamer P-407, soya lecithin, citric acid, potassium dihydrogen 
phosphate, disodium hydrogen phosphate, sodium chloride (Loba 
chemie Pvt. Ltd, Mumbai). 
Method 
In this study, A 32
Y= b 
full factorial experimental design was used to 
optimize the formulation of nanoparticles. In the present 
investigation concentration of Lipid (X1) and concentration of 
Surfactant (X2) were selected as independent variables. The 
entrapment efficiency and particle size were selected as dependent 
variables. A statistical model incorporating interactive and 
polynomial terms was used to evaluate the response. 
0+b 1X1+B 2X2+B 12 X 1X2+B 11 X12+B 22 X 22
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Independent variable 
Table 1: Coding of actual values of variables 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
X1 -1 0 +1 -1 0 +1 -1 0 +1 
X2 -1 -1 -1 0 0 0 +1 +1 +1 
X1: Lipid (stearic acid): 33.31 (1:20 milimoles), 66.62 mg (1: 40 milimoles), 99.93 (1:60 milimoles), X2 Surfactant (soya Lecithin): 100 mg (1%), 300 
mg (3 %), 500 mg (5%)  
 
Preparation of paclitaxel-loaded solid lipid nanoparticles 
The microemulsion of paclitaxel was prepared by melting stearic 
acid at 80 ° C to which paclitaxel was added and stirred for 5 min. 
Soya lecithin was added to this mixture and stirred for 5 min. 
Aqueous phase consisted of poloxamer P 407. Citric acid was 
added to maintain pH 5 and heated at 80 °C. This mixture was then 
added to the melted lipid phase. This solution was kept on probe 
sonicator for a period of 10 min at 79 amplitude. Finally, o/w 
emulsion was formed. This microemulsion was carefully added 
dropwise into ice cold water present in the beaker with 
continuous stirring at 2000 rpm on the magnetic stirrer. The SLN 
dispersion was stirred for 2 hr after addition of microemulsion. 
This prepared microemulsion was further pass through High-
Pressure Homogenizer (HPH) keeping the pressure at 900 bars. 
The resultant SLN was characterized [15]. 
 
Table 2: Formulation of Paclitaxel SLNs 
Ingredients (mg) Batches 
P1 P2 P3 P4 P5 P6 P7 P8 P9 
Paclitaxel 5 mg 
Stearic Acid mg 33.31 33.31 33.31 66.62 66.62 66.62 99.93 99.93 99.93 
Poloxamer P 407 mg 28.59 28.59 28.59 57.18 57.18 57.18 85.77 85.77 85.77 


















Distilled water upto 20 ml with ice cold water 
 
Characterization of paclitaxel solid lipid nanoparticles 
Particle size analysis 
The particle size and polydispersity index (PDI) of prepared solid 
lipid nanoparticles were determined using a Malvern Zetasizer ZS90 
(Nano series Malvern Instrument). Each sample was diluted 10 
times with distilled water to avoid multiscattering phenomena and 
is placed in disposable sizing cuvette and analyzed the particle size 
and PDI. The ploydispersibility index was studied to determine the 
narrowness of particle size distribution. The size analysis of sample 
consisted of 3 measurements and results were expressed as mean 
size±Std. Deviation [15]. 
Zeta potential measurements 
Zeta potential is the potential difference between the dispersion 
medium and the stationary layer of fluid attached to the dispersed 
particle. Zeta potential is a key indicator of the stability of colloidal 
dispersions. The magnitude of the zeta potential indicates the degree 
of electrostatic repulsion between adjacent, similarly charged particle 
in the dispersion. The zeta potential of prepared Paclitaxel solid lipid 
nanoparticles was determined using a Malvern Zetasizer ZS90 (Nano 
series Malvern Instrument). The preconcentrated paclitaxel SLNs 1 ml 
sample was diluted 10 times with distilled water in 10 ml volumetric 
flask. From this solution, 1 ml is placed in disposable zeta potential 
cuvette. The zeta limits ranged from-200 to+200mV [16]. 
Determination of % entrapment efficiency 
Entrapment efficiency of Paclitaxel-loaded solid lipid nanoparticle was 
estimated by the centrifugation method. The cooling centrifuge was 
used. In this method prepared solid lipid nanoparticles were placed in 
centrifugation tube and centrifuged at 2000 rpm for 20 min at 6-8 °C. 
The supernatant was withdrawn and pellets were washed with water. 
This was then kept in the cooling centrifuge at 15000 rpm for 40 min 
at 6-8 °C. The supernatant layer was removed and pellets were 
collected and diluted with methanol. By using UV spectrophotometer 
entrapped Paclitaxel was determined at 230 nm. The samples from 
pellets were diluted before going for absorbance measurement. The 
amount of paclitaxel loaded in pellets gives the total amount of 
entrapped drug. The concentration of drug was calculated from the 
straight line equation obtained from the standard calibration curve of 
Paclitaxel. Encapsulation efficiency is also expressed as a percent of 
drug trapped and was calculated using equation [17]. 
 
% Drug loading capacity 
Loading capacity (LC %) can be calculated by the amount of total 
entrapped drug divided by the total nanoparticle weight. In drug 
delivery, yield, given as a percent, is a reflection of the amount of 
drug delivered per amount encapsulated. Loading capacity helps you 
to deal with nanoparticles after their separation from the medium 
and to know their drug content [18]. It is calculated by using the 
following equation;  
 
Shape and surface morphology 
Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM) are very useful in determining the shape and 
morphology of lipid nanoparticles and allow determination of 
particle size and distribution. TEM determines the particle size with 
or without staining. SEM uses electrons transmitted from the 
specimen surface, while TEM uses electrons transmitted through the 
specimen. TEM allows visualization of SLNs after freeze fracturing 
and freeze substitution. Transmission Electron Microscopy was used 
to visualize the morphology of solid lipid nanoparticle. By using 
TEM, various characteristics like particle size, shape and internal 
structure of nanoparticulate carriers system can be efficiently 
evaluated. 
Procedure 
The surface morphology and shape of the optimized paclitaxel SLN 
were analyzed by TEM. The sample was diluted with double distilled 
water and then placed on copper grids coated with carbon film 
before negative staining with 2% (w/v) sodium phosphotungstic 
acid solution for observation. 
In vitro drug release 
In vitro drug release was evaluated by using a dialysis bag diffusion 
technique. (Dialysis membrane with a molecular weight cut off 
12,000). 
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The procedure of in vitro study 
The release of paclitaxel from the solid lipid nanoparticles was 
measured in triplicate in Phosphate Buffer Saline (pH 7.4). In PBS pH 
7.4, 0.5% Tween was added. 2 mg equivalent paclitaxel SLN was 
taken in a dialysis bag and both the ends of dialysis bag were closed 
and placed in a beaker containing 75 ml PBS pH 7.4. This dialysis bag 
was arranged in such a way that it just touches the surface of the 
buffer solution. The whole set up was placed on a magnetic stirrer 
which was rotated at 50rpm. The temperature of buffer was 
maintained at 37±1 °C. 2 ml aliquots of release medium were 
withdrawn at a time interval 0.5, 1, 2, 4, 8, 12, 24 and 48 h. To 
maintain the sink condition, the same volume of dissolution media 
was added. The aliquots were centrifuged at 3000rpm for 5 to 10 
min at room temperature. The supernatant was diluted with 
methanol and estimated by UV visible spectrophotometer at 230 nm. 
The concentration of drug was calculated from the straight line 
equation obtained from standard curve of paclitaxel [19]. 
 
RESULTS AND DISCUSSION 
Table 3: Effect of Stearic acid and soya lecithin on particle size, PDI, Zeta potential, % EE and %DLC 
Batch  Average particle size nm PDI* Zeta potential (mV)*  * % Entrapment efficiency % Drug loading capacity* * 
P1 152±1.1 0.321±3.10 -25.8±1.29 75.29±3.20 2.24±0.09 
P2 154±2.1 0.415±1.35 -27.7±2.87 80.39±2.66 1.09±0.04 
P3 149±4.1 0.250±2.04 -29.7±0.77 93.38±1.90 0.81±0.01 
P4 156±4.0 0.333±1.50 -24.3±1.12 79.88±2.61 1.74±0.06 
P5 159±4.9 0.425±2.10 -23.8±1.65 84.17±2.36 0.97±0.03 
P6 166±1.5 0.355±3.20 -22.6±1.10 94.23±2.76 0.732±0.01 
P7 259±4.5 0.321±2.75 -21.7±3.5 80.79±1.96 1.38±0.03 
P8 262±2.8 0.280±2.50 -20.2±2.40 84.65±2.25 0.85±0.02 
P9 265±1.4 0.259±1.25 -18.7±2.51 95.46±2.33 0.69±0.01 
All the values are expressed as mean±SD, n=3 
 
The particle size is the most important property for in vivo 
integrity and biological fate of nanoparticles. The average particle 
size of paclitaxel SLNs were found in between 149±4.1 nm and 
265.0±1.40 nm. Fig. 1 shown the graph of particle size of Batch P3 
which was best of an average value. The polydispersity indices of 
all batches reveal that all the batches have uniform particle size 
distribution. Batch P3 shows that Average particle size of 149±4.1 
and PDI of 0.250±2.04. 
 
 
Fig. 1: Particle size distribution of batch P3 
 
 
Fig. 2: Zeta potential of batch P3 
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The stability study of prepared solid lipid nanoparticles was 
evaluated by measuring the zeta potential of nanoparticles using 
zeta meter. Zeta potential of P3 batch was-29.7 which indicates no 
agglomeration of the particles hence moderate stability. The 
increased concentrations of soya lecithin have not affected the zeta 
potential as revealed by the zeta potentials of the batches P1, P2 and 
P3. As the concentration of stearic acid is increased from batch P4 to 
P9, the zeta potential went on decreasing. Fig. 2 shown the zeta 
potential graph of batch P3 which was best of an average value. 
Drug entrapment efficiency is an important property in drug-loaded 
nanocarriers and directly affects the therapeutic effect of system. 
The entrapment efficiencies of all the batches have been shown in 
table 3 The results show that the amount of drug entrapped is 
increased with increase in the concentration of Stearic acid or soya 
lecithin. All the batches with highest concentration of Stearic acid 
(P3, P6 and P9) have shown highest entrapment efficiency. This may 
be attributed to the higher intactness of lipid. An increased 
concentration of soya lecithin increases entrapment efficiency by 
improving the film strength to increase the amount of drug in the 
nanoparticles. The highest entrapment was observed in batch P9 i.e. 
95.46%. The higher the encapsulation capacity of nanoparticles the 
larger the amount of drug released at the tumor site. The graphical 
representation was shown in fig. 3. 
 
 
Fig. 3: Graphical representation of % entrapment efficiency (mean±SD, n=3) 
 
The batches P1, P2, P3, P4 and P7 have exhibited good drug loading 
capacities, their magnitude being above 0.8 %. Out of these batches 
P1, P2 and P3 batches produced the particles in the desired particle 
size range. However, the P1 and P2 batches produced non-
homogenous oily dispersions which led to their physical instability. 
Considering the parameters like particle size, drug loading capacity 
and physical stability of the formulation P3 batch has performed 
well in all aspects. Hence, it was treated to be optimized batch. 
 
 
Fig. 4: TEM of Batch P3 
The TEM study of optimized paclitaxel SLN illustrated the spherical 
shape of nanoparticles. The TEM image of the nanoparticles is 
depicted in fig. No. 4 It is evident from the image that the particles 
were spherical in shape with narrow size distribution and no 
aggregation. Particles of optimized paclitaxel SLN formulation were 
of nanosize. The surface of particles is smooth moreover their 
integrity was found to be intact. 
Optimization of paclitaxel SLNs 
Data analysis of Y1 entrapment efficiency (% EE) 
The % EE of paclitaxel SLNs was determined by using 
ultracentrifugation method. The entrapment efficiency varied from 
75.29±3.20% to 95.46±2.33%. The results clearly indicated that Y1 
is strongly affected by the amount of Lipid (stearic acid) and the 
amount of surfactant (soya lecithin) selected for the study. The 
response Y1 obtained at various levels of two independent variables 
was subjected to multiple regressions to give a quadratic polynomial 
equation. 
The quadratic polynomial equation as follow:  
Y1=+84.06+1.97A+7.85B-0.8550AB-1.25A2+3.28B
Two-dimensional contour plots and 3-D response surface plots for 
variables Y 1 (% EE) are shown in fig. 6 and fig. 7 respectively. Fig. 6 
and fig. 7 reveal an increase in entrapment efficiency (95.465) with 
an increase in the amount of lipid (stearic acid) and the amount of 
surfactant (soya lecithin) led to increases in %entrapment efficiency. 
The highest entrapment efficiency was obtained with the highest 
amount of lipid. 
2 
Contour plots and response surface analysis 
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Fig. 5: Contour plot for Y1 (% EE) 
 
 
Fig. 6: Response surface plot for Y1 (%EE) 
 
Data analysis of Y2 (Particle size) 
The particle size and PDI results of all the 9 batches of paclitaxel SLNs 
are tabulated in table 5. 22. The particle size of P1-P9 Batches was found 
in the range of 149.53±4.14 to 265.06±1.40 and the PDIs were in the 
range of 0.250±2.04 to 0.425±2.10. The results indicated an effect of the 
amount of stearic acid and soya lecithin on particle size. The response Y2 
obtained to various levels of two independent variables was subjected in 
multiple regressions to give a quadratic polynomial equation. 
Y2=+159.95+55.07 A+2.13B+2.24AB+47.27A2+0.2390B
Two-dimensional contour plots and 3-D response surface plots for 
variables Y2 (Particle size) are shown in fig. 8and fig. 9 respectively. 
Fig. 8 and fig. 9 reveals that an increase in the amount of lipid led to 
an increase in particle size (265.06±1.40 nm). The lowest particle 
size was reported with the highest amount of surfactant and the 
lowest amount of lipid reveal a decline in particle size (149.53±4.14 
nm) with an increase in the amount of surfactant. But the effect of 
surfactant (soya leithin) was less on particle size Y2 than the effect 
of Lipid (stearic acid). 2 
Contour plots and response surface analysis 
Raut et al. 




Fig. 7: Response surface plot for Y2 (Particle size) 
 
 
Fig. 8: Contour plot for Y2 (Particle size) 
 
Optimization 
The final optimal experimental parameter was calculated using 
optimization technique in the design expert softwares. This is used 
after generating the model polynomial equation which is to relate 
the dependent and independent variables. The design expert 
software was used which allows to compromise among the various 
responses and combination of factor level that jointly optimize the 
set of response by satisfying the requirement of each response in the 
set.
  
Table 4: Result of optimized batch P3 
S. No. Response Experimental value Predicted value 
1 % Entrapment Efficiency 93.38 94.17 
2 Particle Size 149.53 145.06 
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Table 5: Formula of optimized batch P3 
S. No. Ingredients Quantity 
1. Paclitaxel 5 mg 
2. Stearic acid 33.31 mg 
3. Soya lecithin 500 mg 
4. Poloxamer (407) 28.50 mg 
5. Distilled Water 20 ml 
 
Table 6: Evaluation parameter of optimized batch P3 of PTX SLN 
S. No. Ingredients Quantity 
1. % Entrapment Efficiency 93.38 
2. Particle Size 149.53±4.14 
3. PDI 0.250±2.04 
4. Zeta potential -29.7±0.77 
5. % DLC 0.81±0.01 
6. In vitro drug release  78.68±1.87 
*The value are expressed as mean±SD, n=3 
 
In vitro drug release of optimized paclitaxel solid lipid nanoparticles 
In vitro drug release study of paclitaxel nanoparticles of 
optimized batch, P3 was studied by dialysis bag approach in PBS 
pH7.4 with tween 80. The weight of prepared Paclitaxel SLN 
equivalent to 2 mg drug was placed in the activated dialysis bag 
which is kept in phosphate buffer saline pH 7.4 and performed in 
vitro drug release study. UV method was used for analyzing the 
data instead of HPLC which was used already. (15) The sustained 
release of paclitaxel with an initial burst release effect from lipid 
delivery system was observed. The sustained release of 
paclitaxel from nanoparticles may be the effect of localization of 
drug within the lipid matrix. Stearic acid being more lipophilic 
had sustained the release. The poloxamer, used as a surfactant, 
coated the nanoparticles. This coat prevented the degradation of 
nanoparticles in an acidic environment and the structural 
integrity was maintained. The % cumulative drug release 
observations are tabulated in table 7. 
Treatment of in vitro drug release data with different kinetic 
equations 
The in vitro release study of optimized paclitaxel SLN was 
performed using a dialysis bag approach in PBS pH 7.4. The data of 
the in vitro drug release was used in different kinetic release 
pattern and the in vitro kinetic profile is tabulated in table 5. 
 
Table 7: In vitro drug release profile of optimized paclitaxel SLN 
S. No. Time (h) Average percent cum* 
1.  0 0 
2.  0.5 6.24±1.89 
3.  1 11.96±2.31 
4.  2 17.31±3.43 
5.  4 24.86±2.95 
6.  8 40.83±2.68 
7.  12 51.97±2.74 
8.  24 64.22±2.80 
9.  48 78.68±1.87 
*
 
The value are expressed as mean±SD, n=3 
 
Fig. 9: In vitro drug release profile of batch P3 mean±SD, n=3 
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Table 5: In vitro drug release profile treated with kinetic equations 
S. No. Time Cumulative % drug release Log % amt release % drug remaining Log % drug remaining 
1.  0 0 0 100 2 
2.  0.5 6.24 0.795 93.76 1.972 
3.  1 11.96 1.077 88.04 1.945 
4.  2 17.31 1.238 82.69 1.917 
5.  4 24.86 1.395 75.14 1.876 
6.  8 40.83 1.611 59.17 1.772 
7.  12 51.97 1.715 48.03 1.682 
8.  24 64.22 1.807 35.78 1.554 
9.  48 78.68 1.901 20.32 1.308 
  
Table 6: Model fitting 
R Zero-order 2 Peppas Higuchi First order 
0.8209 0.9772 0.9735 0.9511 
 
The formulation followed peppas plot equation. This indicates that 
the PTX nanoparticle followed more than one type of release 
phenomenon and it appeared to be by the non fickian diffusion 
control mechanism. 
CONCLUSION 
The SLNs of paclitaxel met al. l the requirements of a colloidal drug 
delivery system. They had a particle size in nanosize; their size 
distribution was narrow and all the particles were in a spherical 
shape. The percent entrapment efficiency and percent drug loading 
capacities were in the acceptable limits. Moreover, the in vitro 
release pattern revealed that they served the purpose of being a 
sustained drug delivery system. 
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